home / stock / ocup / ocup news

OCUP News and Press, Ocuphire Pharma Inc Com From 11/03/23

Stock Information
Company Name: Ocuphire Pharma Inc Com
Stock Symbol: OCUP
Market: NASDAQ
Website: ocuphire.com
Menu
OCUP OCUP Quote OCUP Short OCUP News OCUP Articles OCUP Message Board
Get OCUP Alerts

News, Short Squeeze, Breakout and More Instantly...
OCUP - Expected US Company Earnings on Friday, November 3rd, 2023

HST Global Inc (HSTC) is expected to report for quarter end 2023-09-30 Air China Ltd ADR - Level I (AIRYY) is expected to report for Q3 2023 GrafTech International Ltd. (EAF) is expected to report $-0.05 for Q3 2023 Cardinal Health Inc. (CAH) is expected to report $1.4 for Q1 2024 ...
OCUP - Expected earnings - Ocuphire Pharma Inc.

Ocuphire Pharma Inc. (OCUP) is expected to report $-0.32 for Q3 2023

OCUP - Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy

Agreement on Phase 3 Primary Endpoint of 3-step Worsening on Binocular Diabetic Retinopathy Severity Scale (DRSS) Score Company Plans to Submit a Special Protocol Assessment (SPA) APX3330 has the Potential to be the First Oral Option for 8M Non-Proliferative Diabetic Retinop...

OCUP - Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FARMINGTON HILLS, Mich., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that...
OCUP - Ocuphire Pharma appoints George Magrath as CEO

2023-11-01 08:41:26 ET More on Ocuphire Pharma Viatris and Ocuphire Pharma announce FDA approval for eye drop formulation RYZUMVl Seeking Alpha’s Quant Rating on Ocuphire Pharma Historical earnings data for Ocuphire Pharma Financial information for Ocu...

OCUP - Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director

FARMINGTON HILLS, Mich., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced the ...

OCUP - Ocuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcase

FARMINGTON HILLS, Mich., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced pres...
OCUP - Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October

FARMINGTON HILLS, Mich., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced pres...

OCUP - Viatris and Ocuphire Pharma announces FDA approval for their eye drop formulation

2023-09-27 09:22:17 ET More on Ocuphire Pharma, Viatris, etc. Why 5%-Yielding Viatris Hasn't Doubled Yet Viatris Emerges As Challenger In Lucrative Anti-Obesity Drugs Market Viatris: Turning Point For Cheap Pharma Stock Viatris in talks to sell European OTC a...

OCUP - Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI(TM) (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g.,

FARMINGTON HILLS, Mich., and PITTSBURGH, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders and ...
Previous 10 Next 10